Jazz Pharmaceuticals plc, of Dublin, reported results at the SLEEP meeting in Denver from a human abuse liability study of JZP-110, an investigational wake-promoting agent in phase III development for the treatment of excessive sleepiness in adult patients with narcolepsy or with obstructive sleep apnea. Read More
Clinigen Group plc, of Staffordshire, U.K., said its Idis Global Access division signed an exclusive supply agreement with Galen Ltd., a privately owned pharmaceutical sales and marketing company. Under terms of the supply agreement, Idis will provide Galen's chemotherapy drug Daunoxome (daunorubicin citrate - 2 mg/ml-concentrate for solution for Infusion) to health care professionals on an on-demand basis in 20 European countries, Australia, New Zealand and Hong Kong, where it is unlicensed at the point of care. Galen retained the rights to supply Daunoxome in the U.K. and selected countries outside Europe. It has Medicines and Healthcare products Regulatory Agency approval to treat AIDS-related Kaposi's sarcoma. Read More
Attendees are accustomed to hearing results from phase III trials of investigational agents at the annual meeting of the American Society of Clinical Oncology (ASCO). And at the 2016 meeting, which ran from June 3-7, there were some of those presentations. But the denizens of McCormick Place found themselves contending with somewhat atypical fare this year, with less than the usual buzz around such trials. Read More
A House subcommittee confronted the consequences of kicking the antibiotics can down the road, as lawmakers delved into the U.S. response to the growing global emergence of superbugs. Read More
Mesoblast Ltd. lost more than a third of its market value Tuesday (NASDAQ:MESO) as Teva Pharmaceutical Industries Ltd. returned full development and commercialization rights to its advanced chronic heart failure therapy, MPC-150-IM. Mesoblast CEO Silviu Itescu sought to cast the return as "a major win" for the company, simultaneously announcing a equity financing facility that will fund the program through completion. Read More
Infinity Pharmaceuticals Inc. stunned investors early Tuesday by disclosing disappointing results from the registration-focused DYNAMO study. The phase II trial, which evaluated the efficacy and safety of duvelisib – the oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma – as a monotherapy in 129 patients with refractory indolent non-Hodgkin lymphoma (iNHL), met its primary endpoint by demonstrating an overall response rate (ORR) of 46 percent. Read More
